SCHEMBL844164

SCHEMBL844164

BrCc1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
PDGFRB P09619 2/20 0.50
PDGFRA P16234 2/20 0.50
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
BIRC5 O15392 1/20 0.46
MGAM O43451 1/20 0.46
ALDH1A1 P00352 3/20 0.45
RAB9A P51151 1/20 0.44
PDE10A Q9Y233 5/20 0.43
CYP2A6 P11509 1/20 0.43
GLA P06280 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ACHE P22303 1/20 0.43
CFTR P13569 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1161085 0.98 CYP1A2 (0.50) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL20593103 0.85 CYP1A2 (0.48) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL3396692 0.83 CYP1A2 (0.55) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL5720341 0.81 CYP1A2 (0.48) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL3820110 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL6597946 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL701411 0.80 ALDH1A1 (0.53) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL5742994 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL5700742 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL151560 0.80 CYP1A2 (0.57) CYP1A2PDGFRBPDGFRAKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850241-B Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof 中国药科大学 2025-01-14 CN disclosed
US-20240391901-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2024-11-28 US disclosed
US-20240270695-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) 2024-08-15 US disclosed
CN-117946031-A Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors 北京大学 2024-04-30 CN disclosed
EP-4277897-A1 FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER Chengdu Anticancer Bioscience, Ltd. (CN) 2023-11-22 EP disclosed
CN-116710442-A Compounds, compositions and methods for treating disorders 成都安泰康赛生物科技有限公司 2023-09-05 CN disclosed
WO-2023046055-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING α-KETONE FRAMEWORK, AND USE THEREOF 中国药科大学 2023-03-30 WO disclosed
CN-115850241-A Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof 中国药科大学 2023-03-28 CN disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 US disclosed
WO-2022152097-A1 FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER Chengdu Anticancer Bioscience, Ltd. (CN) 2022-07-21 WO disclosed
WO-2003068791-A2 MACROLIDES WITH ACTIVITY AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ABBOTT LABORATORIES (US) 2003-08-21 WO disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed
US-6147097-A METHOD FOR TREATING AIDS SHIONOGI & CO., LTD. (JP) 2000-11-14 US disclosed
US-5910506-A IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC SHIONOGI & CO., LTD. (JP) 1999-06-08 US disclosed
EP-0786455-A1 IMIDAZOLE DERIVATIVE SHIONOGI & CO., LTD. (JP) 1997-07-30 EP disclosed
WO-1995011895-A1 N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS CIBA-GEIGY AG (CH) 1995-05-04 WO disclosed
US-5173496-A Antiinflammatory agents ICI PHARMA (FR) 1992-12-22 US disclosed
EP-0284174-B1 THERAPEUTIC PREPARATIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-29 EP disclosed
US-4804404-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1989-02-14 US disclosed
EP-0284174-A1 Therapeutic preparations IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270695-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, PNLIP, GOT2 CYP1A2 655/4885PDGFRB 4581/4885PDGFRA 4587/4885
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds DHFR, CYC1, CYCS CYP1A2 201/4885PDGFRB 1181/4885PDGFRA 1162/4885
US-20240391901-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF FAAH, FAAH2, FAH CYP1A2 1045/4885PDGFRB 654/4885PDGFRA 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.